Adc Therapeutics SA (ADCT) — SEC Filings
Adc Therapeutics SA (ADCT) — 38 SEC filings. Latest: 8-K (May 4, 2026). Includes 17 8-K, 6 10-Q, 5 SC 13G/A.
View Adc Therapeutics SA on SEC EDGAR
Overview
Adc Therapeutics SA (ADCT) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 10, 2025: ADC Therapeutics SA (ADCT) reported a net loss of $40.966 million for the three months ended September 30, 2025, a slight improvement from the $43.969 million net loss in the same period of 2024. For the nine months ended September 30, 2025, the net loss widened to $136.214 million from $127.119 mil
Sentiment Summary
Across 38 filings, the sentiment breakdown is: 2 bearish, 36 neutral. The dominant filing sentiment for Adc Therapeutics SA is neutral.
Filing Type Overview
Adc Therapeutics SA (ADCT) has filed 17 8-K, 3 DEFA14A, 6 10-Q, 3 DEF 14A, 2 10-K, 5 SC 13G/A, 1 SC 13G, 1 SC 13D/A with the SEC between Jan 2024 to May 2026.
Filings by Year
Recent SEC Filings (38)
Risk Profile
Risk Assessment: Of ADCT's 25 recent filings, 2 were flagged as high-risk, 13 as medium-risk, and 10 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $58,299,000 |
| Net Income | -$136,214,000 |
| EPS | -$1.14 |
| Debt-to-Equity | N/A |
| Cash Position | $234,738,000 |
| Operating Margin | -177.7% |
| Total Assets | $289,758,000 |
| Total Debt | $455,376,000 |
Key Executives
- Stephen Evans-Freke
- Peter B. Corr
Industry Context
The oncology drug development sector, particularly in the niche of antibody-drug conjugates (ADCs), is highly competitive and capital-intensive. Companies like ADC Therapeutics operate in an environment driven by scientific innovation, lengthy and expensive clinical trials, and stringent regulatory hurdles. Success hinges on demonstrating clinical efficacy and safety to gain market approval and achieve commercial viability against established players and emerging biotechs.
Top Tags
material-agreement (4) · 10-Q (4) · proxy-statement (4) · sec-filing (3) · corporate-governance (3) · financials (3) · governance (3) · corporate-action (3) · asset-sale (3) · royalty-sale (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss | $136.214M | for the nine months ended September 30, 2025, widened from $127.119M in 2024 |
| Net Cash Used in Operating Activities | $110.051M | for the nine months ended September 30, 2025 |
| Total Revenue | $16.427M | for the three months ended September 30, 2025, decreased from $18.464M in 2024 |
| Product Revenues, net | $15.750M | for the three months ended September 30, 2025, decreased from $18.016M in 2024 |
| License Revenues and Royalties | $7.060M | for the nine months ended September 30, 2025, significantly increased from $1.033M in 2024 |
| Cash and Cash Equivalents | $234.738M | as of September 30, 2025, decreased from $250.867M at December 31, 2024 |
| Restructuring, Impairment and Other Related Costs | $13.468M | for the nine months ended September 30, 2025 |
| Net Loss Per Share | $0.30 | for the three months ended September 30, 2025, improved from $0.42 in 2024 |
| Total Revenue, Net | $41.872M | for six months ended June 30, 2025, up from $35.463M in 2024 |
| Research and Development Expenses | $59.018M | for six months ended June 30, 2025, up from $50.030M in 2024 |
| Net Cash Provided by Financing Activities | $94.054M | for six months ended June 30, 2025 |
| Total Liabilities | $520.745M | as of June 30, 2025 |
| Total Assets | $321.561M | as of June 30, 2025 |
| Common Shares Outstanding | 112,499,395 | as of August 1, 2025 |
| Fiscal Year | 2024 | Reporting period for the 10-K |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Adc Therapeutics SA (ADCT)?
Adc Therapeutics SA has 38 recent SEC filings from Jan 2024 to May 2026, including 17 8-K, 6 10-Q, 5 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of ADCT filings?
Across 38 filings, the sentiment breakdown is: 2 bearish, 36 neutral. The dominant sentiment is neutral.
Where can I find Adc Therapeutics SA SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Adc Therapeutics SA (ADCT) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Adc Therapeutics SA?
Key financial highlights from Adc Therapeutics SA's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for ADCT?
The investment thesis for ADCT includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Adc Therapeutics SA?
Key executives identified across Adc Therapeutics SA's filings include Stephen Evans-Freke, Peter B. Corr.
What are the main risk factors for Adc Therapeutics SA stock?
Of ADCT's 25 assessed filings, 2 were flagged high-risk, 13 medium-risk, and 10 low-risk.
What are recent predictions and forward guidance from Adc Therapeutics SA?
Forward guidance and predictions for Adc Therapeutics SA are extracted from SEC filings as they are enriched.